Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer
Authors:
- Christine De BruynCBChristine De Bruyn
- Jolien CeustersJCJolien Ceusters
- Chiara LandolfoCLChiara Landolfo
- Thaïs BaertTBThaïs Baert
- Gitte ThirionGTGitte Thirion
- Sandra ClaesSCSandra Claes
- Ann VankerckhovenAnn Vankerckhoven
- Roxanne WoutersRWRoxanne Wouters
- Dominique ScholsDSDominique Schols
- Dirk TimmermanDTDirk Timmerman
- Ignace VergoteIVIgnace Vergote
- An CoosemansACAn Coosemans
Open Access
Abstract
In monotherapy, immunotherapy has a poor success rate in ovarian cancer. Upgrading to a successful combinatorial immunotherapy treatment implies knowledge of the immune changes that are induced by chemotherapy and surgery. Methodology: Patients with a new d ovarian cancer diagnosis underwent longitudinal blood samples at different time points during primary treatment. Results.: Ninety patients were included in the study (33% primary debulking surgery (PDS) with adjuvant chemotherapy (ACT), 61% neo-adjuvant chemotherapy (NACT) with interval debulking surgery (IDS), and 6% debulking surgery only). Reductions in immunosuppression were observed after NACT, but surgery reverted this effect. The immune-related proteins showed a pronounced decrease in immune stimulation and immunosuppression when primary treatment was completed. NACT with IDS leads to a transient amelioration of the immune microenvironment compared to PDS with ACT. Conclusion: The implementation of immunotherapy in the primary treatment schedule of ovarian cancer cannot be induced blindly. Carboplatin–paclitaxel seems to ameliorate the hostile immune microenvironment in ovarian cancer, which is less pronounced at the end of primary treatment. This prospective study during primary therapy for ovarian cancer that also looks at the evolution of immune-related proteins provides us with an insight into the temporary windows of opportunity in which to introduce immunotherapy during primary treatment.Keywords
Funding Information
- Kom op tegen kanker (Stand up to Cancer) (2016/10728/2603 and 2019/11955/1 to AC and 11758 to AVK)
- Olivia Fund (2017/LUF/00135 to AC)
- Amgen Chair for Therapeutic Advances in Ovarian Cancer (2017/LUF/00069 to IV)
- Vriendtjes tegen Kanker (2016_LUF_00078 to IV)
This publication has 43 references indexed in Scilit:
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerObstetrical & Gynecological Survey, 2012
- A Phase 3 Trial of Bevacizumab in Ovarian CancerNew England Journal of Medicine, 2011
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapyCancer Immunology, Immunotherapy, 2009
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- Recovery of CD8+ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian CancerCancer Research, 2005
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 2004
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003